Drugs / TCMCB07
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05529849 | Jul → Dec 2022 | hypoproteinemia, hypercatabolic | Endevica Bio | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2024-11-12 | Endevica Bio | Results Endevica Bio Drug Candidate Shows Promise for Alleviating Chemotherapy-Induced Anorexia and Weight Loss, Study Shows endevicabio.com ↗
Results showed an increased appetite and stabilized body weight, with preservation of fat and heart mass. |
| 2024-11-07 | Endevica Bio | Results Melanocortin-4 receptor antagonist TCMCB07 alleviates chemotherapy-induced anorexia and weight loss in rats endevicabio.com ↗
Our results indicate that peripheral administration of TCMCB07 improved appetite, stabilized body weight, preserved fat and heart mass, and slightly protected lean mass after multiple cycles of chemotherapy. |
| 2023-10-28 | Endevica Bio | Results Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexia endevicabio.com ↗
Significant changes detected included increased mean body weight (18.6-19.5 kg, P < .02), increased body condition score (median Tufts 5-point thin dog scale score P < .004 and WSAVA muscle condition score P < .02) and increased mean blood urea nitrogen (21.79-30.43 mg dL−1, P < .004). |
| 2023-05-20 | Endevica Bio | Results Preliminary data from the phase I study of TCMCB07, a study to assess the safety, tolerability and pharmacokinetics of the melanocortin antagonist TCMCB07 in healthy subjects. endevicabio.com ↗
In a preliminary analysis of the results, there were no subjects with abnormal vital signs, no subjects with abnormal electrocardiograms, and no drug-related serious adverse events. |
| 2023-05-20 | Endevica Bio | Results Effect of melanocortin-4 receptor antagonist TCMCB07 on chemotherapy-induced anorexia and weight loss in rats. endevicabio.com ↗
Total food intake over 21 days was significantly increased in Cis/TCMCB07 vs Cis/saline group (p = 0.0006) and 5-FU/TCMCB07 vs 5-FU/saline group (p = 0.0134), and decreased in Cis/saline vs Saline/saline group (p = 0.001), but was no significant change in Cis/TCMCB07 vs Saline/saline group and 5-FU/saline or 5-FU/TCMCB07 vs Saline/saline group. |
| 2022-05-01 | Endevica Bio | Results Development of a Therapeutic Peptide for Cachexia Suggests a Platform Approach for Drug-like Peptides endevicabio.com ↗
Based on this, we designed an MC4R antagonist peptide, TCMCB07, that successfully treated many forms of cachexia. |
| 2021-05-20 | Endevica Bio | Results Pharmacokinetics and safety of TCMCB07, a melanocortin-4 antagonist peptide in dogs endevicabio.com ↗ |
| 2020-07-29 | Endevica Bio | Results Characterization of the cellular transport mechanisms for the anti-cachexia candidate compound TCMCB07 endevicabio.com ↗
TCMCB07 inhibited the uptake of prototypical substrates in cells transfected with OATP1A2 (IC50 24.0 μM), OATP1B1 (IC50 6.8 μM), OATP1B3 (IC50 307 μM), OATP2B1 (IC50 524 μM), OCT2 (IC50 1,169 μM), MATE1 (IC50 8.7 μM), and MATE2-K (IC50 20.7 μM) |
| 2020-06-16 | Endevica Bio | Results Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease–associated cachexia endevicabio.com ↗
Our data show that peripheral treatment using TCMCB07 with intraperitoneal, subcutaneous, and oral administration increased food intake and body weight and preserved fat mass and lean mass during cachexia and LPS-induced anorexia. |
All press releases naming this drug 9 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCMCB07 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05529849 ↗ |
| Route | Subcutaneous | “Subcutaneous injection of TCMCB07” NCT05529849 ↗ |